Clinical trials: Severe Preeclampsia
- Condition Severe Preeclampsia
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Pre-eclampsia
Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia
Preeclampsia is one of the leading causes of maternal and fetal death. It is a syndrome of pregnant women and is usually characterized by new onset of hypertension and proteinuria after 20 weeks of gestation.
- Trial name
- NCT07327255
- Testing
- EG-101
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Evergreen Therapeutics, Inc.